Experts Discuss CELMoD Agents for Treating Multiple Myeloma
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
-
Narrado por:
-
De:
In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:
- Combination strategies
- Adverse event management
- Where CELMoD agents may best fit within current and future treatment strategies
Presenters:
Jesus Berdeja, MD
Director of Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee
Amrita Krishnan, MD, FACP
Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Orange County
Professor Hematology/HCT
Irvine, California
Niels van de Donk, MD, PhD
Professor of Hematology
Department of Hematology
Amsterdam UMC, Location VUmc
Amsterdam, Netherlands
Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.
Link to full program:
https://bit.ly/4qvRwQM
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.